BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Drug Development

  MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors

  First patient dosed in Phase I clinical study to evaluate MaxCyte’s lead CAR therapeutic in ovarian cancer and peritoneal mesothelioma

  October 10, 2018

   · 

  3 min read
• Business

  Rheos Medicines Expands Leadership Team with Appointments of Gad Soffer as Chief Operating Officer and J. Duncan Higgons to Board of Directors

  Biopharmaceutical executives bring substantial global business development and operations experience to advance immunometabolism for novel medicines

  October 10, 2018

   · 

  4 min read
• Drug Development

  New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018

  Ozanimod showed effects on cognitive processing speed in a post hoc analysis of 12-month data from SUNBEAM™ pivotal trial

  October 10, 2018

   · 

  9 min read
• BioCapital

  March Of Dimes Calls For #BlanketChange

  March of Dimes, the nonprofit organization leading the fight for the health of all moms and babies, today launched #BlanketChange, ARLINGTON, Va. , Oct. 10, 2018 /PRNewswire/ -- March of Dimes, the nonprofit organization leading the fight for the health of all moms and babies, today la

  October 10, 2018

   · 

  3 min read
• Pharm Country

  Gotham Therapeutics Launches with $54 Million Series A

  Versant-seeded company translating insights about RNA-modifying protein targets into drug candidates

  October 10, 2018

   · 

  7 min read
• Camurus to Present at Jefferies 2018 London Healthcare Conference

  Camurus today announced that that the Company will present at the Jefferies 2018 London Healthcare Conference 14 November at 4:40 pm local time (GMT).

  October 10, 2018

   · 

  1 min read
• Biotech Bay

  OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression Over Five Years in Relapsing and Primary Progressive Multiple Sclerosis

  People with relapsing MS (RMS) treated sooner with OCREVUS had earlier reduction in disease activity and less disability progression vs. those who switched from interferon beta-1α

  October 10, 2018

   · 

  14 min read
• Business

  TopAlliance and UTHealth Sign a Patent and Technology License Agreement

  Access Novel Antibody Technology

  October 10, 2018

   · 

  2 min read
• Business

  Collaboration Between National Physical Laboratory and Mediso

  AnyScan (SPECT/CT/PET) triple modality system

  October 10, 2018

   · 

  2 min read
• DelMar Announces Further Validation of the Mechanism of Action of VAL-083

  DelMar Pharmaceuticals, Inc. today announced the publication of a peer-reviewed scientific paper on the mechanism of action for VAL-083, the Company’s product candidate, in Cell Death and Disease by Nature Publishing Group.

  October 10, 2018

   · 

  5 min read